APA (7th ed.) Citation

Hadden, R. D. M., Andersen, H., Bril, V., Basta, I., Rejdak, K., Duff, K., . . . Ay, H. (2024). Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial. Journal of the Peripheral Nervous System, 29(4), 441. https://doi.org/10.1111/jns.12672

Chicago Style (17th ed.) Citation

Hadden, Robert D. M., et al. "Long‐term Safety and Tolerability of Hyaluronidase‐facilitated Subcutaneous Immunoglobulin 10% as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 Trial." Journal of the Peripheral Nervous System 29, no. 4 (2024): 441. https://doi.org/10.1111/jns.12672.

MLA (9th ed.) Citation

Hadden, Robert D. M., et al. "Long‐term Safety and Tolerability of Hyaluronidase‐facilitated Subcutaneous Immunoglobulin 10% as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 Trial." Journal of the Peripheral Nervous System, vol. 29, no. 4, 2024, p. 441, https://doi.org/10.1111/jns.12672.